News

Brilinta is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs) and it works by inhibiting platelet activation. The sNDA is

Earlier this month, Mylan offered to buy Perrigo in a deal valued at nearly $29bn, under which Perrigo shareholders would receive $205 per share. However, board of directors

The company’s all-natural Tapout product line includes their high potency Omega 3 Fish Oil supplements and all-natural, gluten free, protein shakes. The deal is part of Axxess’s aim

The company believes that the claims made in this litigation were without merit, and it did not admit liability. Currently, the diabetes drug will be available as a

IC, commonly referred to as painful bladder syndrome (PBS), is a chronic disease characterized by bladder pressure, bladder pain, urinary urgency and/or urinary frequency. It affects an estimated

The company said that this first-in-human trial is currently open at Horizon Oncology in Lafayette, Indiana, Sarah Cannon Research Institute in Nashville, Tennessee, the John Theurer Cancer Center

Navidea previously announced its intention to decrease its R&D expenses by divesting its non-core neuroimaging assets. This agreement follows through on the Company’s commitment to decrease cash burn

The acceptance of the NDA indicates the application is sufficiently complete to permit a substantive review by the FDA. "The FDA’s acceptance of our NDA filing brings us

"We are pleased that Triolimus has been designated an orphan drug for the treatment of angiosarcoma," commented Dr. Kevin Kozak, co-founder and Chief Medical Officer of Co-D Therapeutics.